CureVac (NASDAQ:CVAC) Stock Rating Reaffirmed by JMP Securities

CureVac (NASDAQ:CVAC)‘s stock had its “market outperform” rating reiterated by investment analysts at JMP Securities in a report released on Monday, Benzinga reports. They presently have a $16.00 target price on the stock. JMP Securities’ target price would indicate a potential upside of 387.80% from the company’s previous close.

CureVac Trading Up 0.3 %

Shares of CVAC stock opened at $3.28 on Monday. CureVac has a 12-month low of $2.21 and a 12-month high of $8.04. The company has a current ratio of 2.29, a quick ratio of 2.28 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $3.33 and its 200 day moving average is $3.28. The stock has a market capitalization of $734.33 million, a P/E ratio of -2.47, a P/E/G ratio of 2.15 and a beta of 2.62.

CureVac (NASDAQ:CVAC) last issued its earnings results on Thursday, August 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). CureVac had a negative return on equity of 57.18% and a negative net margin of 422.66%. The company had revenue of $15.55 million during the quarter, compared to analysts’ expectations of $10.07 million. Research analysts expect that CureVac will post 0.05 earnings per share for the current year.

Institutional Investors Weigh In On CureVac

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ballentine Partners LLC purchased a new position in shares of CureVac during the 1st quarter worth $38,000. Bank of New York Mellon Corp bought a new stake in shares of CureVac during the 2nd quarter valued at $54,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of CureVac during the 4th quarter valued at $68,000. Signaturefd LLC grew its position in shares of CureVac by 232.0% during the 2nd quarter. Signaturefd LLC now owns 22,043 shares of the company’s stock valued at $75,000 after acquiring an additional 15,403 shares during the period. Finally, Aristides Capital LLC bought a new stake in shares of CureVac during the 4th quarter valued at $100,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.